T WO GENERAL APPROACHES HAVE emerged for the development of selective biological catalysts: genetic modification of enzyme active sites and chemical modification of biological or synthetic receptors with catalytic groups. These efforts have not only resulted in the generation of novel catalysts but have also provided a greater understanding of the mechanisms of enzymatic reactions. Recently, we and others have demonstrated that antibody-combining sites are also attractive starting points for the generation ofselective catalysts, since they bind ligands with high 10 . J. P. Ferris et al., J. Mol. Evol. 11, 293 (1978) . 11 . The HCN concentrations used in this and in other studies can similarly not be regarded as "prebiotic." Solutions of 0.1 to 1M are chosen to produce a measurable set ofproducts within a reasonable time. That such concentrations would not have been possible in a prebiotic ocean can be appreciated from the fact that the total nitrogen now present at the surface of the Earth would produce no more than a 0.2M solution if totally converted to HCN and dissolved in the present oceans. High concentrations ofHCN can, however, be produced by freezing very dilute solutions, and this process has been proposed to have operated on the prebiotic Earth (1). 12 affinity and specificity (1) . A number of strategies have been applied to the generation of antibodies that catalyze a variety of reactions with rate enhancements of 102 to 106 (2) (3) (4) (5) . Site-directed mutagenesis should prove useful for increasing the activity of these catalytic antibodies, or for the stepwise evolution of antibody-combining sites into efficient selective catalysts. We describe the substitution of a catalytic His residue for Tyr at position 34 of the light chain of the 2,4-dinitrophenyl (DNP)-binding antibody MOPC315 (6, 7) . TyrS4L was previously shown to be in close proximity to the binding site by affinity labeling experiments (8 1 45 times as rapidly, with a rate enchancement of -90,000 compared to 4-methylimidazole. The MOPC315 antibody binds a variety of DNP ligands with association constants of 103 to 107M-' (8, 9) and can be proteolyzed with pepsin to yield functional Fab' or Fv fragments (10) . The Fv fragment (26 kD ) is a heterodimer consisting of two peptides, VH (14 kD) and VL (12 kD), and contains all of the sequences necessary for folding of the binding domain and recognition of the DNP hapten. Although the atomic coordinates for MOPC315 have not been determined, magnetic resonance spectroscopy (11) (12) (13) and affinity labeling (8) studies have provided some information concernig binding site structure.
Because imidazole acts as a nucleophilic catalyst for the hydrolysis of carboxylate esters in aqueous solutions, introduction of a His at the appropriate position in the combining site of MOPC315 should result in a catalytic antibody with specific hydrolytic activity towards DNP-containing esters. Data from chemical modification experiments were used to target residues for substitution with His. Although 14 potentially reactive side chains occur in the hypervariable region (2 His, 2 Lys, 3 Arg, and 7 Tyr), DNP-containing affinity labels alkylate primarily two residues, Tyr34L and Lys52H (4, 8) . The reactivity ofeach residue strongly depends on the number of atoms between the DNP ring and the electrophilic carbon of the affinity reagent; Tyr34L is alkylated SCIENCE, VOL. 245
Generation of a Catalytic Antibody by Site-Directed Mutagenesis
ENOCH BALDWIN AND PETER G. SCHULTZ* A hybrid Fv fragment of the dinitrophenyl-binding immunoglobulin A (IgA), MOPC315, has been generated by reconstituting a recombinant variable light chain (VL) produced in Escherichia coli with a variable heavy chain (VH) derived from the antibody. The Tyr34 residue of VL was substituted by His in order to introduce a catalytic imidazole into the combining site for the ester hydrolysis. The His mutant Fv accelerated the hydrolysis of the 7-hydroxycoumarin ester of 5-(2,4-dinitrophenyl)aminopentanoic acid 90,000-fold compared to the reaction with 4-methyl imidazole at pH 6.8 and had an initial rate that was 45 times as great as that for the wild-type Fv. The hydrolyses ofaminopropanoic and aminohexanoic homologs were not significantly accelerated. Thus a single deliberate amino acid change can introduce significant catalytic activity into an antibody-combining site, and chemical modification data can be used to locate potential sites for the introduction of catalytic residues. most efficiently by 4, whereas Lys52H reacts with 5 ( Fig. 1 ). Pollack et al. have previously exploited this data by using cleavable affinity labels to introduce a thiol (4), and subsequently a catalytically active imidazole (5) into the MOPC315 combining site at position 52H. We chose Tyr34L for mutagenesis since it appeared that a His34L side chain would be well situated to catalyze the hydrolysis ofesters 1 through 3 ( Fig. 1) (4, 5) .
The role of Tyr34L in DNP binding has not been clearly established: affinity labeling of the Tyr hydroxyl to form the 2-keto-5-thiolpentyl ether prevents binding of ligands (4), perhaps by blocking the entrance to the site, while nitration has no effect (13) . Tyr34L is conserved in murine A light chains and is found frequently in K chains and in heavy chains at the analogous position (position 33) (22) . We also substituted Phe at position 34L to assess the contribution of the Tyr hydroxyl group to hapten binding.
In order to generate mutant MOPC315 combining sites, we chose to express the VL portion of the Fv domain of the antibody in Escherichia coli. Eukaryotic disulfide-containing proteins are often produced in E. coli in a reduced insoluble form and must be subsequently renatured to the native state (14) . Reduced and separated VH and VL peptides of MOPC315 have been recombined to yield a stable Fv (10) . The single disulfide bond in VH or VL can be formed by oxidation of the reduced forms prior to reconstitution. The simplicity and efficiency of reconstitution makes the Fv a desirable target for expression of an antibody-combining site in E. coli. We exploited this property to produce a hybrid Fv, in which recombinant VL produced in E. coli is reconstituted with VH derived from MOPC315 IgA. Expression of functional Fv (15) and Fab (16) fragments in bacteria by secretion has also been reported. A gene encoding the first 115 amino acids of MOPC315 light chain (22) was designed and chemically synthesized ( Fig. 2A) , and expressed as a fusion with the X cII gene (17) (Fig. 2B ). The NH2-terminal extension of the cII-VL hybrid was removed by sitespecific cleavage with factor Xa (18) . The liberated VL peptide was reconstituted with antibody-derived VH, and the resulting Fv was purified by gel filtration and affinity chromatography ( Fig. 3 ). Antibody-derived VH was prepared by denaturing ion-exchange chromatography of authentic MOPC315 Fv, which was obtained from pepsin digestion of purified IgA, and subsequent affinity chromatography. Pepsin treatment afforded two major VH peptides and a small amount of incompletely digested VHcontaining fragments, which copurified. were incorporated. Otherwise, the most frequently occurring E. coli codons were used. A gene consisting of these sequences was constructed from four restriction fragments (Eco RI-Bst ElI, Bst ElI-Ava II, Ava II-Bss HII, and Bss HII-Hind III, denoted by the arrows above the sequence). Complementary synthetic oligonucleotides 78 to 99 bases in length were phosphorylated, annealed, and ligated into a derivative ofM13mpl8, either singly or as a pair. The cloned segments were sequenced and assembled into the full-length gene in several steps. Cassette and primer mutagenesis (23) were used to make subsequent modifications, which resulted in the deletion ofthe Eco RI site. (B) Expression vector pLcIIFXVL. The synthetic VL genes were expressed as a fusion with the cII gene of coliphage A (17) . A synthetic duplex encoding the factor Xa recognition and cleavage sequence, Ile-Glu-Gly-Arg, was inserted in-frame at the 5' end of the VL gene in M13. The P-globin gene in the expression vector pLcIIFX,(nic-) (17) was excised by digestion with Bam HI and Hind III and replaced by the hybrid FXVL sequence. The Tyr34 mutations [Tyr34(TAT) to His(CAT) and Phe(T17T)] were made in the VL gene in M13 by the method of Kunkel (23) and then transferred into pLcIIFXVL by substitution of the Bst ElI-Hind III fragment. 4A ) (values are reported ± SE). These data suggest that the Tyr hydroxyl group is not important for recognition of the DNP moiety. DNP-aminoalkyl carboxylic acids of different lengths (6 through 9, Fig. 1 ) (9) were used to probe the location of the positively charged imidazole ring with respect to the DNP site in Fv(Y34HL) at pH 6.0. The relative affinities of Fv(Y34HL) for these ligands (7>8>9>6) are different from that of the Fv(315) (9>7>8>6). In general, Fv(Y34HL) binds 6 through 9 one-half to one-eighth as tightly as Fv(315), consistent with its lower affinity for DNP Lys at pH 6.8. In contrast to Fv(315), Fv(Y34HL) binds 7 and 8 most tightly, suggesting a compensating electrostatic interaction between the negatively charged carboxylate of the ligand and the protonated imidazolium side chain.
The ability of wild-type and mutant Fvs to hydrolyze esters 1 through 3 was assayed by measuring the rate of coumarin release fluorimetrically at pH 6.8 (4, 5) . Fv(Y34HL) efficiently hydrolyzes 1 in a manner consistent with Michaelis-Menten kinetics (Michaelis constant Km = 2.2 + 0.2 ,uM, rate constant kcat = 0.18 ± 0.03 min-, and kcatlKm = 8.2 x 104M-' min-, pH 6.8) ( Fig. 4B and Table 1 ). Under these conditions, Fv(Y34HL) tuMs over at least 11 times and still retains 44% of its activity. The loss of activity probably results from the accumulation of the inhibitory reaction product 8. The Fv-catalyzed reaction was competitively inhibited with DNP Lys (inhibition constant K1 = 3.8 ± 1.5 ,uM) (19) . Ester 2 was a poor substrate cantly accelerated by Fv(Y34HL), which is consistent with the preference for ligands 7 and 8, and the affinity-labeling data. The initial rate of hydrolysis of 1 by Fv(Y34HL) at pH 6.8 is -45-fold as fast as the reaction with either Fv(Y34FL) or Fv(315) ( Table  1) . At pH 8.7, the reactivity of Fv(Y34HL) and Fv (3 15) The imidazole-acylating agent diethylpyrocarbonate rapidly and completely inhibits the hydrolysis of 1 at pH 6.0 (5, 20) , supporting a catalytic role for His34. The imidazole side chain of His34 could catalyze the hydrolysis of ester by three mechanisms: (i) nucleophilic attack on the ester carbonyl to form a labile imidazolide intermediate, which is then rapidly hydrolyzed; (ii) activation of an attacking water molecule; and (iii) electrostatic stabilization of the negatively charged transition-state created by hydroxide ion attack on the ester carbonyl. The maximum velocity Vlmax of Fv(Y34HL) hydrolysis of 1 increases linearly by only a factor of 3 from pH 5.6 to 8.6. This result suggests that the rate-limiting step of hydrolysis does not involve simple hydroxide ion attack, since such a reaction should be first order in hydroxide ion concentration. Because Fv(Y34HL) is also more active at higher pH (where the neutral form of imidazole predominates), it seems unlikely that the observed rate acceleration is simply due to electrostatic stabilization. At present we have no evidence supporting either of the CaCI2, and kanamycin sulfate (30 Rg/ml) was incubated for 30 hours, 37°C with 600 ,ug of bovine factor X [prepared from the BaSO4 eluate of bovine plasma (17, 18) (Sigma)] activated in situ with 2.5 ,g of crude Russell's viper venom (Sigma). Crude VL was made 100 mM in NaCl and passed through a 2-mil bed of Q-sepharose, dialyzed against distilled water, lyophilized, and dissolved in 8M urea and 20 mM potassium phosphate, pH 6.0. Fv(315) was purified from ascites fluid from MOPC315 myeloma grown in BALB/c mice as previously described (6, 10) , except that the gel filtration step after pepsin cleavage was omitted. The VH peptide was separated from VL by ion-exchange chromatography (Pharmacia mono Q 10/10 column) in 20 mM tris-Cl, pH 8.0, and 8M urea, with a 0 to 250 mM NaCl gradient. Cleaved VL (0.1 to 1 mg) and equimolar VH were rapidlv diluted tenfold from 8M urea into 100 mM potassium phosphate, pH 6.0 (final protein concentration = 50 ,ug/nml) and allowed to stand 30 min at 25°C. Active Fv, was adsorbed onto DNP-lysine sepharose (10, 24) , washed with 100 mM NaCl and 50 mM tris-Cl, pH 8.0 and eluted with a small volume of 30 mM DNP-glycine, pH 8.0. The eluate was dialyzed against 100 mMl potassium phosphate, pH 6.8. Overall yield from the fusion protein is 5 to 20%. The vield of reconstitution is 20 to 30% based on VH. Residual VL dimer or DNP-glycine was removed by gel-filtration fast protein liquid chromatography (FPLC) on a Superose 12 column in 100 mM potassium phosphate, pH 6.8. Hybrid Fv, reconstituted in this fashion has the same affinity for DNP-L-lVsine as Fv purified from pepsin-treated MOPC3 15 IgA that was not reconstituted. Because of convenience, myeloma-produced Fv(315) was used in this study. Protein purity was assessed by electrophoresis through 14% polyacrylamide SDS gels (25) followed by Coomassie staining and by gel filtration FPLC analysis with a Superose 12 column (flow rate of 0.5 ml/min, sample size of 100 jig). II06 other mechanisms, although imidazole derivatives hydrolyze active esters primarily by the nucleophilic pathway in aqueous solution (7) .
In order to assess the contributions of the binding site to hydrolysis of 1, we compared the Fv(Y34HL) catalyzed reaction with the reaction with 4-methylimidazole under the assay conditions (5) . The ratio of the bimolecular rate constants (kcat/Km)Ik4-MeIm is 9 ± 3 x 104 (21) . This rate acceleration is similar to that of an antibody that contains an active site carboxylate that acts as a specific base in the catalysis of an elimination reaction (3) . The rate of hydrolysis of 1 by Fv(Y34HL) can also be compared with that of MOPC315 Fab that has been chemi- We have demonstrated the feasibility of using site-directed mutagenesis to introduce a catalytically active residue into an antibody combining site. In the absence of highresolution structural information, chemical cross-linking data have proven useful in identifying sites for the introduction of catalytic groups. Additional site-directed or random mutagenesis combined with in situ screens or selections could be used to generate more efficient catalytic antibodies. Alternatively, Cys residues could be introduced for the subsequent attachment of synthetic catalysts to produce semisynthetic catalytic antibodies (5) . most characteristic clinical feature of the chronic phase of CML is an increase in mature and immature myeloid elements in bone marrow and peripheral blood (3) . Kinetic studies indicate that these abnormal cells do not proliferate or mature faster than the normal counterpart (4) . Rather, the basic defect underlying the exuberant granulopoiesis in CML appears to be an expansion of the myeloid progenitor cell pool in bone marrow and peripheral blood (5) . Although hematopoiesis in the chronic phase of CML is altered, it retains some normal features. These observations raise the possibility that c-abl function is required during normal human hematopoiesis.
Inhibition of specific gene functions by exposing target cells to synthetic antisense oligomers (6) was used to investigate the role of c-myb in normal human hematopoiesis (7, 8) . We have now used the same technique to show that exposure of early and late hematopoietic progenitors to c-abl antisense oligomers inhibits in vitro myelopoiesis and spares erythropoiesis. This suggests a lineage-specific requirement of c-abl function in normal hematopoiesis. 8 
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Lineage-Specific Requirement of c-abl Function in Normal Hematopoiesis DANIELE CARACCIOLO, MAURO VALTIERI, DONATELLA VENTURELLI, CESARE PESCHLE, AiAN M. GEWIRTZ,* BRUNO CALABRETrA* Structural abnormalities of the c-abl proto-oncogene are found in hematopoietic cells of more than 90 percent of individuals with chronic myelogenous leukemia. Therefore c-abl may be important in normal as well as malignant hematopoiesis. Normal human hematopoietic progenitor cells were exposed to three different c-abl sense or antisense oligodeoxynudeotides, and the effects on myeloid and erythroid colony formation were examined. The c-abl antisense oligodeoxynucleotides inhibited myeloid, but not erythroid, colony formation. The c-abl sense oligodeoxynudeotides and bcr sense and antisense oligodeoxynucleotides were not inhibitory in this assay. These data show that c-abl is critical in normal myelopoiesis and may explain the relatively selective expansion of leukocytes in patients with chronic myelogenous leukemia.
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